Birmingham Women's Hospital; and the Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom
Financial Disclosure: Dr. Clark received £50,000 from Cytyc (now Hologic), which manufactures the NovaSure ablation system, which was used to fund a research fellow. Dr. Clark is a member of the European Advisory Board for Hologic and has received travel expenses, honoraria for lectures, and surgical training paid into a research account from Cytyc (now Hologic). Drs. Clark and Gupta have received travel expenses, honoraria for lectures, and surgical training paid into a research account from Gynecare (now Ethicon Women's Health & Urology). The other authors did not report any potential conflicts of interest.